In vitro activity of BAY 12-8039, a new fluoroquinolone

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 1, 1997, Pages 101-106

  Woodcock, J M ^a   Andrews, J M ^a   Boswell, F J ^a   Brenwald, N P ^a   Wise, R ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 7 (2,8 DIAZABICYCLO[4,3,0]NON 8 YL) 6 FLUORO 8 METHOXY 1,4 DIHYDRO 4 OXO 3 QUINOLINE; AMOXICILLIN; CEFPODOXIME; CIPROFLOXACIN; CLAVULANIC ACID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; DOSE TIME EFFECT RELATION; ENTEROBACTERIACEAE; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION;

EID: 0031037471     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.1.101     Document Type: Article

References (12)

1. British Society for Antimicrobial Chemotherapy Working Party. 1991. A guide to sensitivity testing. British Society for Antimicrobial Chemotherapy, London, United Kingdom.
2. Child, J., J. M. Andrews, F. Boswell, N. P. Brenwald, and R. Wise. 1995. The in-vitro activity of CP99219, a new naphthyridine antimicrobial agent: a comparison with fluoroquinolone agents. J. Antimicrob. Chemother. 35:869-876.
3. Dalhoff, A., U. Peterson, and R. Endermann. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy (Basel), in press.
4. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering. 1993. In vitro activity of CP 99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
5. Endermann, R., and K. D. Bremm. 1992. BAY y3118, a novel 4-quinone: activity against anaerobes, abstr. 645. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Hospital Infection Society Working Party. 1995. Guidelines on the control of methicillin-resistant Staphylococcus aureus in the community. J. Hosp. Infect. 31:1-12.
7. Isaacs, R. D., P. J. Kunke, R. L. Cohen, and J. W. Smith. 1988. Ciprofloxacin resistance in epidemic methicillin resistant Staphylococcus aureus. Lancet ii:843.
8. 7a. Pearson, R. D., R. T. Steigbel, H. T. Davis, and S. W. Chapman. 1980. Method for reliable determination of minimum lethal antibiotic concentrations. Antimicrob. Agents Chemother. 18:690-708.
9. Perronne, C., A. Gikas, C. Tuffot-Pernot, J. Grosset, J.-J. Pocidalo, and J.-L. Vilde. 1990. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob. Agents Chemother. 34:1508-1511.
10. Raviglione, M. C., J. F. Boyle, P. Mariuz, A. Pablos-Mendez, H. Cortes, and A. Merlo. 1990. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob. Agents Chemother. 34:2050-2054.
11. Wakabayashi, E., and S. Mitsuhashi. 1994. In vitro activity of AM-1155, a novel 6-fluoro-3-methoxy quinolone. Antimicrob. Agents Chemother. 38: 594-601.
12. Webberley, J. M., R. S. Matthews, J. M. Andrews, and R. Wise. 1987. Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur. J. Clin. Microbiol. 6:587-589.